Venue: Seminar Hall, Main Building
Speaker: Dr. Ravi PN Mishra, Principal Scientist Biological E. Ltd., Hyderabad
Abstract:
The stringent regulatory guidelines and increasing demand emphasized the need for the production of well characterized & high quality biotherapeutic proteins. My presentation will be focused on expression, scale up and large scale production of a Biotherapeutic protein, CRM197. CRM197 is a genetically detoxified mutant of diphtheria toxin (DT, ~58 kD) and primarily used as carrier protein in several licenced vaccines used to immunize hundreds of millions of childrens and adults worldwide. These vaccines are used for prevention of important bacterial pathogens such as Streptococcus pneumoniae (Prevnar), Haemophilus influenzae type b (HibTITER, Vaxem-Hib) and Neisseria meningitidis serogroup A, C, Y and W-135 (e.g. Menveo and Menjugate) [1]. CRM197 protein is also known for its anti-tumor properties as it inhibits the Heparin-binding epidermal growth factor-like growth factor (HB-EGF). The anti-cancer properties of CRM197 has been for the development of cancer biotherapeutitics [2]. The presentation will focus on Fermentation of E.coli expressing CRM197 protein, downstream processing/purification of bioactive protein and in-depth characterization of protein using biophysical, biochemical and immunological tools. In the second part of my presentation a short detail about development of staphylococcal therapeutic proteins will be described. These protein are under evaluation in Phase-1 and targeted to be used for active and passive immunotherapy against hospital acquired MDR Staphylococcus aureus.
Screen Reader Access